These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17193687)

  • 1. MRI tumor characterization using Gd-GlyMe-DOTA-perfluorooctyl-mannose-conjugate (Gadofluorine M), a protein-avid contrast agent.
    Raatschen HJ; Swain R; Shames DM; Fu Y; Boyd Z; Zierhut ML; Wendland MF; Misselwitz B; Weinmann HJ; Wolf KJ; Brasch RC
    Contrast Media Mol Imaging; 2006; 1(3):113-20. PubMed ID: 17193687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging.
    Daldrup-Link HE; Shames DM; Wendland M; Mühler A; Gossmann A; Rosenau W; Brasch RC
    Acad Radiol; 2000 Nov; 7(11):934-44. PubMed ID: 11089696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    AJR Am J Roentgenol; 1998 Oct; 171(4):941-9. PubMed ID: 9762973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    Pediatr Radiol; 1998 Feb; 28(2):67-78. PubMed ID: 9472047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation.
    Preda A; Novikov V; Möglich M; Floyd E; Turetschek K; Shames DM; Roberts TP; Corot C; Carter WO; Brasch RC
    Eur Radiol; 2005 Nov; 15(11):2268-75. PubMed ID: 16012822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology.
    Turetschek K; Floyd E; Helbich T; Roberts TP; Shames DM; Wendland MF; Carter WO; Brasch RC
    J Magn Reson Imaging; 2001 Sep; 14(3):237-42. PubMed ID: 11536400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of N-ethyl-N-nitrosourea-induced malignant and benign breast tumors in rats by using three MR contrast agents.
    Su MY; Wang Z; Carpenter PM; Lao X; Mühler A; Nalcioglu O
    J Magn Reson Imaging; 1999 Feb; 9(2):177-86. PubMed ID: 10077011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model.
    Turetschek K; Roberts TP; Floyd E; Preda A; Novikov V; Shames DM; Carter WO; Brasch RC
    J Magn Reson Imaging; 2001 Jun; 13(6):882-8. PubMed ID: 11382948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging of the pancreas in streptozotocin-induced diabetic rats: Gadofluorine P and Gd-DOTA.
    Cho HR; Lee Y; Doble P; Bishop D; Hare D; Kim YJ; Kim KG; Jung HS; Park KS; Choi SH; Moon WK
    World J Gastroenterol; 2015 May; 21(19):5831-42. PubMed ID: 26019447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of Gd-DOTA in magnetic resonance imaging of experimentally induced mammary tumors.
    Bonnet PA; Michel A; Fernandez JP; Cyteval C; Rifai A; Boucard M; Chapat JP; Lamarque JL
    Magn Reson Imaging; 1990; 8(1):71-7. PubMed ID: 2325520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation.
    Turetschek K; Huber S; Floyd E; Helbich T; Roberts TP; Shames DM; Tarlo KS; Wendland MF; Brasch RC
    Radiology; 2001 Feb; 218(2):562-9. PubMed ID: 11161179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues.
    Cyran CC; Fu Y; Raatschen HJ; Rogut V; Chaopathomkul B; Shames DM; Wendland MF; Yeh BM; Brasch RC
    J Magn Reson Imaging; 2008 Mar; 27(3):581-9. PubMed ID: 18219614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology.
    Turetschek K; Floyd E; Shames DM; Roberts TP; Preda A; Novikov V; Corot C; Carter WO; Brasch RC
    Magn Reson Med; 2001 May; 45(5):880-6. PubMed ID: 11323815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors.
    Preda A; Turetschek K; Daldrup H; Floyd E; Novikov V; Shames DM; Roberts TP; Carter WO; Brasch RC
    Invest Radiol; 2005 Jun; 40(6):349-54. PubMed ID: 15905721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a Gadolinium-Based Nanoparticle (AGuIX) for Contrast-Enhanced MRI of the Liver in a Rat Model of Hepatic Colorectal Cancer Metastases at 9.4 Tesla.
    Fries P; Morr D; Müller A; Lux F; Tillement O; Massmann A; Seidel R; Schäfer T; Menger MD; Schneider G; Bücker A
    Rofo; 2015 Dec; 187(12):1108-15. PubMed ID: 26361379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysferlin-deficient muscular dystrophy: gadofluorine M suitability at MR imaging in a mouse model.
    Schmidt S; Vieweger A; Obst M; Mueller S; Gross V; Gutberlet M; Steinbrink J; Taubert S; Misselwitz B; Luedemann L; Spuler S
    Radiology; 2009 Jan; 250(1):87-94. PubMed ID: 19001151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
    Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R
    Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early MR lymphography with gadofluorine M in rabbits.
    Misselwitz B; Platzek J; Weinmann HJ
    Radiology; 2004 Jun; 231(3):682-8. PubMed ID: 15163808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance enhancement pattern and diagnostic accuracy of gadofluorine M in a rabbit VX2 tumor model: Comparison with gadopentetate dimeglumine.
    Kim SJ; Moon WK; Choi SH; Chang JM; Cho N
    Eur J Radiol; 2012 Aug; 81(8):1751-7. PubMed ID: 21477960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.